BackgroundUrothelial carcinoma (UC) is the fifth most common malignancy that accounts for 5% of all cancers. Diagnostic markers that predict UC progressions are inadequate. NF-κB contributes towards disease progression upon constitutive activation in many solid tumors. The nuclear localization of NF-κB indicates increased transcriptional activity while cytoplasmic localization indicates the inactive protein repository that can be utilized readily by a malignant cell. This study delineates the nuclear and cytoplasmic differential expression of NF-κB heterodimers in UC progression.MethodsThe involvement of the NF-κB proteins in UC was analyzed in silico using cytoscape. The expression of NF-κB heterodimers was analyzed by immunohistochemistry.ResultsPINA4MS app in cytoscape revealed over expression of RelA and suppression of NF-κB1 (p50 precursor) in UC whereas the expression of NF-κB target proteins remained unhindered. Immunohistochemical localization showed nuclear RelA/p50 in low grade UC whereas in high grade only RelA expression was observed. Conversely, cytoplasmic expression of RelA/p50 remained extensive across high and low grade UC tissues (p < 0.005). RelA nuclear and cytoplasmic expression (p < 0.005) was directly proportional to the disease progression. In our study, some of the high-grade UC tissues with squamous differentiation and muscle invasion had extensive nuclear p50 localization. The phenomenon of RelA/p50 expression seen increased in low-grade UC than high grade UC might be due to their interaction with other members of NF-κB family of proteins. Thus, NF-κB RelA/p50 differential expression may play a unique role in UC pathogenesis and can serve as a biomarker for diagnosis.
Bladder cancer is a recurrent disease that often develops chemoresistance and is on the rise in developing countries. After diagnosis surgery followed by immunotherapy and/or chemo-radiation therapy are the available treatments. These treatments do not provide protection against disease progression or recurrence thus highlighting the need to identify and develop drugs that are capable of inhibiting bladder cancer. T24 cell line (human bladder transitional cell carcinoma) was treated with NEMO Binding Domain (NBD) peptide and tested for its cytotoxicity, cell cycle inhibition, apoptosis and migration, in vitro. The cytotoxicity of NBD peptide was tested on non-cancerous cells (NIH-3T3-L1, CHO, Vero) and the peptide localization in T24 cells was confirmed using confocal microscopy. The effects of NBD peptide and the standard drugs (cisplatin, gemcitabine) were compared with untreated control. Peptide based chemotherapy for human bladder cells was tested that include combinations of NBD and standard drugs. Statistical significance was assessed between the different treatment groups. The viability of T24 cells after NBD peptide treatment was reduced to 50% at a dose of 18.5 µM after 48 h. The NBD peptide elicited selective cytotoxicity dose-dependently in T24 cells while being non-toxic on normal (non-cancer) cell lines. Sub G0-G1 accumulation of T24 cells was seen where they underwent necrosis and lost the ability to migrate when treated with 100 µM NBD. T24 cell death increased to ~78% when treated with a combination of NBD with cisplatin and gemcitabine (standard drugs) as opposed to ~50% when treated with NBD peptide alone. NBD peptide exhibits specific anti-cancer activity on T24 cells in vitro and found to be non-cytotoxic to select normal cell lines. Combining NBD with standard drugs demonstrated excellent inhibition of malignant growth than the individual anti-neoplastic agents.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.